FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2553702955> ?p ?o ?g. }

• W2553702955 abstract "Background Baricitinib (bari), an oral JAK1 and JAK2 inhibitor, was efficacious in a Ph 3 study (RA-BEAM) in RA patients (pts) with active disease and an inadequate response (IR) to MTX. 1 Objectives To evaluate patient-reported outcomes (PROs) from RA-BEAM. Methods Pts on stable background MTX were randomized to placebo (PBO), bari 4 mg QD, or adalimumab (ADA) 40 mg Q2W. PROs listed in the table and the Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA) were collected on electronic tablets during study visits. Bari vs. PBO and bari vs. ADA were assessed with ANCOVA and logistic regression models. Results 1305 pts were randomized. Functional disability at baseline (mean HAQ-DI) was: 1.55, 1.57, 1.59 for PBO, bari, and ADA, respectively. Compared to PBO, bari was superior in physical function, Pt9s Global Assessment of Disease Activity (PtGDA), pain, fatigue and quality of life (physical component score [PCS]), at Wk 12 and 24. Compared to ADA, bari was superior in physical function, PtGDA, and pain at Wks 12, 24 and 52. Compared to PBO, a similar proportion of bari and ADA pts were employed throughout the study. Statistically significant improvements in all components of the WPAI-RA (absenteeism, presenteeism, work productivity loss and activity impairment) were seen in the bari pts compared to PBO at Wk 12; statistically significant improvements were seen for work loss and activity impairment for bari pts compared to ADA at Wk 12. Conclusions In this Ph 3 study of RA patients with an IR to MTX, treatment with bari resulted in significant improvement in most PROs compared with PBO or ADA, including functional disability, pain, and fatigue. References Taylor et al. Arthritis Rheumatol 2015;67(S10) Disclosure of Interest E. Keystone Consultant for: Abbott Laboratories, AstraZeneca Pharma, Biotest, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Inc, Genentech Inc, Janssen Inc, Eli Lilly and Company, Merck, Pfizer Pharmaceuticals, UCB, P. Taylor Consultant for: Eli Lilly & Company, UCB, Pfizer, Galapagos, AbbVie, Takeda, Bristol-Myers Squibb, Y. Tanaka Consultant for: Eli Lilly & Company, AbbVie, Daiichi-Sankyo, Chugai, Takeda, Mitsubishi-Tanabe, Bristol-Myers Squibb, Astellas, Eisai, Janssen, Pfizer, Asahi-kasei, GlaxoSmithKline, UCB, Teijin, MSD, Santen, Taisho-Toyoma, Kyowa-Kirin, C. Gaich Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, A. DeLozier Employee of: Eli Lilly and Company, A. Dudek Consultant for: Eli Lilly and Company, J. Velasco Zamora Consultant for: Eli Lilly and Company, J. Covarrubias Cobos Consultant for: Eli Lilly and Company, S. de Bono Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, V. Arora Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, L. Yang Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, B. Linetzky Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, M. Weinblatt Consultant for: Eli Lilly & Company, AbbVie, Pfizer, Crescendo Bioscience" @default.
• W2553702955 created "2016-11-30" @default.
• W2553702955 creator A5001548815 @default.
• W2553702955 creator A5008219132 @default.
• W2553702955 creator A5015953107 @default.
• W2553702955 creator A5026750016 @default.
• W2553702955 creator A5028230855 @default.
• W2553702955 creator A5047117557 @default.
• W2553702955 creator A5048983541 @default.
• W2553702955 creator A5049261212 @default.
• W2553702955 creator A5052807793 @default.
• W2553702955 creator A5064075793 @default.
• W2553702955 creator A5073962135 @default.
• W2553702955 creator A5082299919 @default.
• W2553702955 creator A5083522443 @default.
• W2553702955 date "2016-06-01" @default.
• W2553702955 modified "2023-09-26" @default.
• W2553702955 title "THU0609 Patient-Reported Outcomes from A Phase 3 Study of Baricitinib versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis and An Inadequate Response To Background Methotrexate Therapy: Table 1." @default.
• W2553702955 doi "https://doi.org/10.1136/annrheumdis-2016-eular.1239" @default.
• W2553702955 hasPublicationYear "2016" @default.
• W2553702955 type Work @default.
• W2553702955 sameAs 2553702955 @default.
• W2553702955 citedByCount "1" @default.
• W2553702955 countsByYear W25537029552017 @default.
• W2553702955 crossrefType "journal-article" @default.
• W2553702955 hasAuthorship W2553702955A5001548815 @default.
• W2553702955 hasAuthorship W2553702955A5008219132 @default.
• W2553702955 hasAuthorship W2553702955A5015953107 @default.
• W2553702955 hasAuthorship W2553702955A5026750016 @default.
• W2553702955 hasAuthorship W2553702955A5028230855 @default.
• W2553702955 hasAuthorship W2553702955A5047117557 @default.
• W2553702955 hasAuthorship W2553702955A5048983541 @default.
• W2553702955 hasAuthorship W2553702955A5049261212 @default.
• W2553702955 hasAuthorship W2553702955A5052807793 @default.
• W2553702955 hasAuthorship W2553702955A5064075793 @default.
• W2553702955 hasAuthorship W2553702955A5073962135 @default.
• W2553702955 hasAuthorship W2553702955A5082299919 @default.
• W2553702955 hasAuthorship W2553702955A5083522443 @default.
• W2553702955 hasConcept C126322002 @default.
• W2553702955 hasConcept C139719470 @default.
• W2553702955 hasConcept C142724271 @default.
• W2553702955 hasConcept C159110408 @default.
• W2553702955 hasConcept C162324750 @default.
• W2553702955 hasConcept C1862650 @default.
• W2553702955 hasConcept C204787440 @default.
• W2553702955 hasConcept C204983608 @default.
• W2553702955 hasConcept C27081682 @default.
• W2553702955 hasConcept C2777402515 @default.
• W2553702955 hasConcept C2777575956 @default.
• W2553702955 hasConcept C2779951463 @default.
• W2553702955 hasConcept C2780132546 @default.
• W2553702955 hasConcept C2781059491 @default.
• W2553702955 hasConcept C2909065710 @default.
• W2553702955 hasConcept C2910384678 @default.
• W2553702955 hasConcept C2992962319 @default.
• W2553702955 hasConcept C512399662 @default.
• W2553702955 hasConcept C71924100 @default.
• W2553702955 hasConceptScore W2553702955C126322002 @default.
• W2553702955 hasConceptScore W2553702955C139719470 @default.
• W2553702955 hasConceptScore W2553702955C142724271 @default.
• W2553702955 hasConceptScore W2553702955C159110408 @default.
• W2553702955 hasConceptScore W2553702955C162324750 @default.
• W2553702955 hasConceptScore W2553702955C1862650 @default.
• W2553702955 hasConceptScore W2553702955C204787440 @default.
• W2553702955 hasConceptScore W2553702955C204983608 @default.
• W2553702955 hasConceptScore W2553702955C27081682 @default.
• W2553702955 hasConceptScore W2553702955C2777402515 @default.
• W2553702955 hasConceptScore W2553702955C2777575956 @default.
• W2553702955 hasConceptScore W2553702955C2779951463 @default.
• W2553702955 hasConceptScore W2553702955C2780132546 @default.
• W2553702955 hasConceptScore W2553702955C2781059491 @default.
• W2553702955 hasConceptScore W2553702955C2909065710 @default.
• W2553702955 hasConceptScore W2553702955C2910384678 @default.
• W2553702955 hasConceptScore W2553702955C2992962319 @default.
• W2553702955 hasConceptScore W2553702955C512399662 @default.
• W2553702955 hasConceptScore W2553702955C71924100 @default.
• W2553702955 hasLocation W25537029551 @default.
• W2553702955 hasOpenAccess W2553702955 @default.
• W2553702955 hasPrimaryLocation W25537029551 @default.
• W2553702955 hasRelatedWork W2230367379 @default.
• W2553702955 hasRelatedWork W2268500885 @default.
• W2553702955 hasRelatedWork W2339943513 @default.
• W2553702955 hasRelatedWork W2549411495 @default.
• W2553702955 hasRelatedWork W2549701246 @default.
• W2553702955 hasRelatedWork W2552806269 @default.
• W2553702955 hasRelatedWork W2553326149 @default.
• W2553702955 hasRelatedWork W2553598894 @default.
• W2553702955 hasRelatedWork W2555496209 @default.
• W2553702955 hasRelatedWork W2555849547 @default.
• W2553702955 hasRelatedWork W2557230747 @default.
• W2553702955 hasRelatedWork W2754846932 @default.
• W2553702955 hasRelatedWork W2885462375 @default.
• W2553702955 hasRelatedWork W2890600132 @default.
• W2553702955 hasRelatedWork W2901392325 @default.
• W2553702955 hasRelatedWork W2909924915 @default.
• W2553702955 hasRelatedWork W2950872861 @default.
• W2553702955 hasRelatedWork W3082388869 @default.
• W2553702955 hasRelatedWork W3165733823 @default.
• W2553702955 hasRelatedWork W3165824012 @default.
• W2553702955 isParatext "false" @default.

• next